Navigation Links
€12 million ($16.9 million) project to develop new tools for malaria control
Date:3/29/2011

LSTM has launched a collaborative project to develop and evaluate new tools to control the spread of malaria in Africa. AvecNet is a five year, 12 million project involving sixteen partners in Africa and Europe, funded by the European Union's Seventh Framework programme.

Because malaria is transmitted by mosquitoes, their effective control is essential to combating the disease. Wide scale use of insecticides on bednets and in interior spraying programmes has dramatically reduced transmission but continued success is dependent on a very limited range of insecticides and other tools.

AvecNet aims to secure the continued effectiveness of these methods into the future by developing and evaluating new insecticides and techniques that will overcome the growing threat of insecticide resistance, as well as designing new tools and interventions to target the mosquitoes that currently evade these control methods. The project also aims to increase existing knowledge about the biology and behaviour of mosquitoes to enable more effective control as urbanisation and other environmental factors alter the balance in this continuing fight against an evolving and formidable opponent.

Dr Hilary Ranson, Head of the Vector Group at LSTM and leader of AvecNet, said: "We need to secure the viability of existing malaria control programmes and expand their scope and reach by developing new methods and tools based upon a vastly increased understanding of how mosquitoes behave and react in different environments.

"We will also rigorously field test existing and prototype tools and techniques to both inform their further development and refinement and to add to the knowledge base from which we can develop further tools and interventions.

"By increasing research capacity in Africa and Europe and uniting people with skills in lots of different fields we are going to generate the momentum to achieve what we hope will be a number of signifi
'/>"/>

Contact: Billy Dean
william.dean@liv.ac.uk
01-517-053-272
Liverpool School of Tropical Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. £2 million study to reveal workings of dementia genes
2. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
3. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
4. L-1 Identity Solutions Awarded New Massachusetts RMV Drivers License Contract Valued at an Estimated $32 Million
5. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
6. Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen
7. New $11 million center to speed production of new compounds for drug discovery
8. SAIC Awarded $37 Million Contract to Support U.S. Army Program Executive Office - Enterprise Information Systems
9. Eastman Dental Center awarded $1.6 million to find ways to prevent cavities
10. L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million
11. Deep heat solution to 500-million year mystery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... behavior through tiny hairs on the cell surface called cilia. ... not work properly. New research from UC Davis published this ... new insights into how these cilia are assembled. "It,s ... Jonathan Scholey, professor of molecular and cellular biology at UC ...
... Iowa - Bone is one of nature,s surprising "building ... resilient. Scientists at the U.S. Department of Energy,s ... its outstanding properties and the important role citrate plays, ... or prevent bone diseases such as osteoporosis. Using ...
... The world,s largest and least known type of gorilla ... has awarded the Wildlife Conservation Society a $150,000 grant to ... eastern Democratic Republic of Congo. The grant will ... struggle to protect the gorillas of Kahuzi-Biega National Park, a ...
Cached Biology News:How cells' sensing hairs are made 2Citrate key in bone's nanostructure 2Citrate key in bone's nanostructure 3Wildlife Conservation Society receives $150,000 grant from Newman's Own Foundation to save gorillas 2
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Cedara Software , a Merge Healthcare ... has released a new version of its digital imaging ... product is a software development kit (SDK) that now ... connectivity for software applications. , ,DICOM is a set ...
... your building technologically obsolete? Are you paying too much ... a building is very important in the selection process ... to current tenants who are contemplating a move to ... some should be avoided because they offer nothing in ...
... all relevant domain names and misspellings pertaining to its trademark? ... are they free for the taking? Who has rights to ... questions posed by a reader regarding domains in his portfolio. ... principles can be used as guidelines with respect to whether ...
Cached Biology Technology:Making sure YourSpace is technologically sound 2Making sure YourSpace is technologically sound 3Making sure YourSpace is technologically sound 4Making sure YourSpace is technologically sound 5Is your business domain at risk? 2Is your business domain at risk? 3Is your business domain at risk? 4
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: